eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2015
vol. 19
 
Share:
Share:
more
 
 
abstract:
Review paper

Radiotherapy and anthracyclines – cardiovascular toxicity

Dagmara Mozdzanowska, Marek Woźniewski

Contemp Oncol (Pozn) 2015; 19 (2): 93–97
Online publish date: 2014/06/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The subject of this paper is to analyze the impact of radiotherapy and anthracyclines on the cardiovascular system, based on a survey of contemporary literature. Currently, high efficiency of anticancer therapies has increased the rate of survival in patients treated for cancer. It should be emphasized, however, that these treatments damage not only the affected but also the healthy tissue. Consequently, with the increase of survival rate in these patients, the number of patients with complaints regarding numerous organs and systems also increases as a result of earlier treatment. Thus, during the first decade of the 21st century, a number of concerns about the relationship between cancer treatment and dysfunction of the cardiovascular system were resolved. Anthracyclines, as well as radiotherapy, are capable of damaging the cardiovascular system, both at the central level, by the deterioration of cardiac function, and at peripheral levels, by increasing the hemodynamic and thrombotic changes.
keywords:

radiotherapy, anthracyclines, chemotherapy, toxicity, cancer

references:

Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14-25.

Brana I, Tabernero J. Cardiotoxicity. Ann Oncol 2010; 21: 173-9.

Ewer MS, Swain SM, Cardinale D, Fadol A, Suter TM. Cardiac dysfunction after cancer treatment. Tex Heart Inst J 2011; 38: 148-252.

Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23 Suppl 7: vii155-66.

Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24.

Chargari C, Kirov KM, Bollet MA, et al. Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev 2010; 37: 321-30.

Sereno M, Brunello A, Chiappori A, et al. Cardiac toxicity: old and new issues in anticancer drugs. Clin Transl Oncol 2008; 10: 35-46.

Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Buchar) 2013; 8: 59-67.

Dimos AK, Stougiannos PN, Trikas AG. “First, do no harm”: chemotherapy or healthy heart? Hellenic J Cardiol 2012; 53: 127-36.

Galderisi M, Marra F, Esposito R, Lomoriello VS, Pardo M, de Divitiis O. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007; 5: 4.

Heidenreich PA, Kapoor JR. Radiation induced heart disease. Heart 2009; 95: 252-8.

Wittig A, Engenhart-Cabillic R. Cardiac side effects of conventional and particle radiotherapy in cancer patients. Herz 2011; 36: 311-24.

Mesurolle B, Qanadli SD, Merad M, Mignon F, Baldeyrou P, Tardivon A, Lacombe P, Vanel D. Unusual radiologic findings in the thorax after radiation therapy. Radiographics 2000; 20: 67-81.

Przybyszewski WM, Wideł M, Rzeszowska-Wolny J. Kardiotoksyczne następstwa promieniowania jonizującego i antracyklin. Postepy Hig Med Dosw 2006; 60: 397-405.

Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010; 76: 656-65.

Ziółkowska E, Woźniak-Wiśniewska A, Wiśniewski T, Makare¬wicz R, Sinkiewicz W. The influence of radiotherapy on cardiac disorders. Wspolczesna Onkol 2009; 13: 16-21.

Friedlander AH, Sung EC, Child JS. Radiation-induced heart disease after Hodgkin’s disease and breast cancer treatment: dental implications. J Am Dent Assoc 2003; 134: 1615-20.

Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564-75.

Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine 2007; 2: 567-83.

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337.

Karczmarek-Borowska B, Ładna E, Wójcik J. Kardiotoksyczność antracyklin i innych leków przeciwnowotworowych. Diagnostyka i zapobieganie. Onkol Pol 2002; 5: 167-77.

Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009; 16: 1656-72.

Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.

Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012; 11: S21-S36.

Stachowiak P, Kornacewicz-Jach Z, Safranow K. Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy. Arch Med Sci DOI 10.5114/aoms.2013.34987.

Szmit S, Szczylik C. Pegylated liposomal doxorubicin and risk of cardiovascular events. Wspolczesna Onkol 2009; 13: 13-20.

Deptała A, Omyła-Staszewska J, Staszewska-Skurczyńska M. Kardiotoksyczność antracyklin i kardioprotekcja. Fakty i mity. Wspolczesna Onkol 2004; 8: 107-11.

Bręborowicz E, Bręborowicz P, Litwiniuk M, Tomczak P. Kardiomiopatia po leczeniu antracyklinami jako istotny problem diagnostyczny i terapeutyczny w praktyce lekarza onkologa. Wspolczesna Onkol 2007; 11: 204-9.

Szmit S, Opolski G, Szczylik C. Powikłania kardiologiczne jako powikłania terapii celowanych. Wspolczesna Onkol 2008; 12: 318-23.

Gupta D, Shukla P, Munshi A, Aggarwal JP. Cardioprotective radiotherapy: the circadian way. Med Hypotheses 2012; 78: 353-5.

Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 144: 3-15.

Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. The Am J Cardiol 2013; 12: 1688-96.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe